Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this interesting learning session on first line management of ALK positive lung cancer.
In this webinar, a panel discussion would take place involving Dr. Jessicca Lin as the primary speaker and Dr. T. Raja, Dr. Amit Rauthan, Dr. B. K. Smruti and many other panelists who will share the important facts associated with first line management of ALK positive lung cancer.
Starting with the case scenario of non-small cell lung cancer, Dr Jessica has explained all details associated with the incidence, progression and treatment of ALK positive lung cancer. Further, the panel discussion will give more knowledge.
ALK-positive lung cancer represents about 4% of lung cancer which generally appears in adenocarcinoma non-small cell lung cancer. Patients with ALK-positive are mostly younger than the average lung cancer patient and also do not have a smoking history compared to other lung cancers.
Therefore, you are going to have an overall knowledge regarding management of ALK positive lung cancer. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Lung cancer screening adherence rates decline annually after baseline screening
2.
MRI-guided radiation therapy improves quality of life with fewer side effects in patients with localized cancer. JAMA
3.
Weight-Based and Fixed-Dose Pembrolizumab Compared in NSCLC
4.
World's premier cancer institute faces crippling cuts and chaos
5.
Zebrafish models offer fast, effective guidance for personalized therapies for kids with high-risk cancer
1.
The Power of Romiplostim in Treating Low Platelet Counts
2.
Cancer Diagnosis in 2025: Innovations, Education, and Evolving Clinical Strategies
3.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
4.
The Different Types of Cysts and Why They Occur: Insights from a Dermatologist
5.
Protein S-Palmitoylation in Cancer: A Novel Target in Immunotherapy & Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
2.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
4.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
5.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation